Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Michielin

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2011
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)R von Moos, B Seifert, M Simcock, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancersS Pradervand, N Freundler, B Gosztonyi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysisU Dafni, O Michielin, S Martin Lluesma, et al.
Oncoimmunology|November 18, 2016
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses with multiple specificities including a novel DR7-restricted epitopeP Baumgaertner, C Costa Nunes, A Cachot, et al.
ESMO Open|June 7, 2023
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databasesP Martin, Z Tsourti, J Ribeiro, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
ESMO Open|June 1, 2022
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)L Castelo-Branco, Z Tsourti, S Gennatas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Amaral, M Ottaviano, A Arance, et al.
ESMO Open|April 22, 2026
Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upS Piperno-Neumann, M Angi, P A Ascierto, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2011
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)R von Moos, B Seifert, M Simcock, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancersS Pradervand, N Freundler, B Gosztonyi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysisU Dafni, O Michielin, S Martin Lluesma, et al.
Oncoimmunology|November 18, 2016
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses with multiple specificities including a novel DR7-restricted epitopeP Baumgaertner, C Costa Nunes, A Cachot, et al.
ESMO Open|June 7, 2023
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databasesP Martin, Z Tsourti, J Ribeiro, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
ESMO Open|June 1, 2022
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)L Castelo-Branco, Z Tsourti, S Gennatas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Amaral, M Ottaviano, A Arance, et al.
ESMO Open|April 22, 2026
Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upS Piperno-Neumann, M Angi, P A Ascierto, et al.
Pageof 4